209 related articles for article (PubMed ID: 28941245)
1. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
Ligneau X; Shah RR; Berrebi-Bertrand I; Mirams GR; Robert P; Landais L; Maison-Blanche P; Faivre JF; Lecomte JM; Schwartz JC
Br J Pharmacol; 2017 Dec; 174(23):4449-4463. PubMed ID: 28941245
[TBL] [Abstract][Full Text] [Related]
2. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
Delaunois A; Mathy FX; Cornet M; Gryshkova V; Korlowski C; Bonfitto F; Koch J; Schlit AF; Hebeisen S; Passini E; Rodriguez B; Valentin JP
Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
Cavero I; Holzgrefe H
Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
[TBL] [Abstract][Full Text] [Related]
4. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
[TBL] [Abstract][Full Text] [Related]
5. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
[TBL] [Abstract][Full Text] [Related]
6. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.
Qu Y; Gao B; Arimura Z; Fang M; Vargas HM
Clin Transl Sci; 2021 Jul; 14(4):1600-1610. PubMed ID: 33955165
[TBL] [Abstract][Full Text] [Related]
8. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
9. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
10. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.
Li Z; Ridder BJ; Han X; Wu WW; Sheng J; Tran PN; Wu M; Randolph A; Johnstone RH; Mirams GR; Kuryshev Y; Kramer J; Wu C; Crumb WJ; Strauss DG
Clin Pharmacol Ther; 2019 Feb; 105(2):466-475. PubMed ID: 30151907
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
Nalos L; Varkevisser R; Jonsson MK; Houtman MJ; Beekman JD; van der Nagel R; Thomsen MB; Duker G; Sartipy P; de Boer TP; Peschar M; Rook MB; van Veen TA; van der Heyden MA; Vos MA
Br J Pharmacol; 2012 Jan; 165(2):467-78. PubMed ID: 21718297
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
[TBL] [Abstract][Full Text] [Related]
13. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
[TBL] [Abstract][Full Text] [Related]
14. Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects.
Song T; Hao Y; Wang M; Li T; Zhao C; Li J; Hou Y
Phytomedicine; 2023 Apr; 112():154688. PubMed ID: 36738478
[TBL] [Abstract][Full Text] [Related]
15. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.
Roche M; Renauleaud C; Ballet V; Doubovetzky M; Guillon JM
J Pharmacol Toxicol Methods; 2010; 61(3):238-50. PubMed ID: 20117224
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays.
Brown AP; Friedrichs GS; Tang HM; Traebert M; Weber V; Yao N; Yan GX
Int J Toxicol; 2024; 43(3):231-242. PubMed ID: 38327194
[TBL] [Abstract][Full Text] [Related]
17. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
[TBL] [Abstract][Full Text] [Related]
18. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
19.
Boulay E; Troncy E; Jacquemet V; Huang H; Pugsley MK; Downey AM; Venegas Baca R; Authier S
Int J Toxicol; 2024; 43(4):357-367. PubMed ID: 38477622
[No Abstract] [Full Text] [Related]
20. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
